ADmit Therapeutics
VerifiedADmit Therapeutics is focused on Alzheimer's disease (AD) early detection. ADmit Therapeutics will give diagnostic services to drug companies conducting early-stage AD clinical studies. Learn more
Launch date
Employees
Market cap
-
Net debt
-
Enterprise valuation
$24—36m (Dealroom.co estimates Oct 2023.)
Company register number B67146738
Esplugues de Llobregat Catalonia (HQ)
- hard tech
- biotechnology
- horizon europe
- woman founder
- spinout
- eit ecosystem
- eit health
- health it
- eit supernovas
- eicfund
- headstart (eit health)
- medical diagnostics
- european health catapult (eit health)
- headstart 2018 (eit health)
- alzheimers disease
- european health catapult 2018 (eit health)
- epigenetics
- caixa impulse (eit health)
- digital sandbox (eit health)
- digital sandbox 2019 (eit health)
- caixa impulse 2015 (eit health)
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 4559 % | 586 % | (78 %) | 40 % | 43 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (966 %) | (38 %) | (25 %) | (342 %) | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (727 %) | (30 %) | (20 %) | (286 %) | - | - |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
Get premium to view all results
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | $0.0 | round |
| investor investor investor | $0.0 | round | |
| investor | $0.0 | round | |
| N/A | $0.0 | round | |
| investor | $0.0 | round | |
| investor | $0.0 | round | |
* | €5.4m | Seed | |
| Total Funding | 000k | ||
Related Content
Recent News about ADmit Therapeutics
EditMore about ADmit Therapeutics
EditDeveloper of a medical diagnostic test intended to come up with early detection for Alzheimer's disease. The company's diagnostic test is based on an epigenetic analysis in blood samples that covers methylcytosines with next-generation sequencing, enabling medical practitioners to identify Alzheimer's and accelerate the identification of curative drugs in a simplified way.
Keywords: Pharmaceuticals and Biotechnology, Alzheimer Detection, Alzheimer Diagnostics, Alzheimer'S Disease Diagnostics, Diagnostic Test Systems, Diagnostic Testing, Disease Detection.
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.